Numerous life sciences companies are now deliver Medication and treatment through home kits for patients with mental illness. DrAnsay.coma Germany-based company focused on developing “firsts in healthcare” is joining the trend by offering patients in the United States an opportunity to try this psilocybin telemedicine treatment.

Both magic truffles and magic mushrooms contain the same psychedelic compound, psilocybin, from which they are made suitable for microdosing and psychotherapy. Nonetheless, and probably due to the developmental stage of truffles and the resulting lower psilocybin concentration, they are said to a less intense, shorter journey compared to mushrooms.

The company also involved in the business of Online prescriptions for medicines cannabis, advises those interested in the new treatment to a telemedical appointment with an experienced “psychedelic guide” by their side.

Once approved, patients can order a home microdosing kit. The company also advises patients to make arrangements virtual follow-up appointments to optimize the treatment success rate and to monitor side effects or risks that could arise from taking the substance.

For people willing to try but unsure if the psychedelic is a possible treatment option for them, DrAnsay.com suggests virtual Q&A sessions with experts who can further explain the conditions this therapy can help treat, including depression, addiction, and obesity, while also promoting neuroplasticity.

“This is just the first step in making this type of mental health care available to legislators and establishing formal legislation in the United States.” said Founder and managing director dr Can Ansay. “Awareness and acceptance are most important right now and the team at DrAnsay.com is doing everything possible to bring this to the attention of policymakers.”

Photo of Nick Morales on Unsplash